SCHEMBL4930918

SCHEMBL4930918

COC(=O)c1cc(Br)c(C)c(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.50
▸ UCHL1 P09936 1/20 0.49
▸ USP30 Q70CQ3 1/20 0.49
▸ KCNH2 Q12809 2/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ BACE1 P56817 2/20 0.42
▸ MAPT P10636 3/20 0.41
▸ EED O75530 1/20 0.41
▸ RBBP4 Q09028 1/20 0.41
▸ SUZ12 Q15022 1/20 0.41
▸ EZH2 Q15910 1/20 0.41
▸ AEBP2 Q6ZN18 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929222 0.88 LMNA (0.49) LMNAKCNH2MEN1KMT2ASMN1; SMN2
SCHEMBL4256162 0.84 LMNA (0.54) LMNAUCHL1USP30KCNH2NR1H2
SCHEMBL4930893 0.83 LMNA (0.46) LMNAKCNH2MEN1KMT2ASMN1; SMN2
SCHEMBL4930003 0.82 GPR119 (0.45) LMNAMEN1KMT2ASMN1; SMN2CYP2C19
SCHEMBL4932179 0.82 PTPN11 (0.52) LMNAPKMMEN1KMT2ASMN1; SMN2
SCHEMBL31490516 0.80 MAPT (0.52) LMNANR1H2MEN1KMT2ASMN1; SMN2
SCHEMBL4934652 0.80 LMNA (0.47) LMNAKCNH2NR1H2MEN1KMT2A
SCHEMBL10306676 0.79 P2RY12 (0.51) LMNAUCHL1USP30KCNH2NR1H2
SCHEMBL28704626 0.79 LMNA (0.50) LMNAKCNH2NR1H2PKMMEN1
SCHEMBL30414220 0.78 LMNA (0.49) LMNANR1H2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 — — US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 — — US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 — — EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 LMNA 2304/4885UCHL1 3989/4885USP30 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback